Jan
2023
This article from Diagnostics World explores diagnostic trends and features Seer CEO Omid Farokhzad predicting a significant acceleration in multiomics-based precision medicine efforts due in part to expansion of our knowledge of the proteome.
Jan
2023
An article from Inside Precision Medicine on the proteomics advances that have led to deep, high-resolution, large-scale studies, and how integrating genomics with proteomic information is expanding our understanding of the molecular consequences of genetics.
Sep
2022
A new article in the journal Advanced Materials demonstrates the performance of the technology underlying Seer's Proteograph Product Suite, which provides unbiased, deep, and rapid proteomics studies at scale.
Aug
2022
In the August issue of Genetic Engineering & Biotechnology News, Daniel Hornburg, Ph.D., from Seer and José Castro-Perez from SCIEX discuss how nanoparticle-based enrichment and other mass spectrometry refinements are facilitating unbiased, deep, and rapid proteomics.
Aug
2022
Seer VP of Research and Technology Development, Asim Siddiqui, weighs in on the current and future landscape of proteomics, the analytical challenges and opportunities, the development of single-molecule innovations, and what the next frontier of discovery may bring to protein research.
Aug
2022
Read GenomeWeb's report highlighting Seer's release of Proteograph™ Analysis Suite 2.0 and how our new analytic and visualization software tool offers a simpler path for mapping peptide-level variants back to their genetic sources in sample-specific databases, and more.
Aug
2022
Learn how Seer's new proteogenomics workflow, powered by Proteograph™ Analysis Suite 2.0, integrates deep, unbiased proteomics with genomics to enable the discovery of novel biological insights with the click of a button.
Jul
2022
In an interview with Drug Discovery and Development, Seer CEO Omid Farokhzad discusses the applications of Seer’s proteomics technology including biomarker discovery, target identification and multiomics research for cancer or complex disease detection, and the latest results from our customers including pharma and biotech companies, translational and academic labs and CROs.
Jul
2022
In this podcast, Michelle Dubuke, Field Application Scientist at Seer, speaks on the practical applications of mass spectrometry and how researchers are using the tool to discover new biological insight on the Society for Laboratory Automation and Screening podcast New Matter.
Jul
2022
In this interview with Medicine Maker, VP of Proteomics, Daniel Hornburg, Ph.D., shares insights into Seer's work analyzing proteomes of astronauts and collaborating with TRISH, NASA, Cornell Medicine, and SpaceX.
Jun
2022
Seer Proteograph™ Product Suite is being used by TruDiagnostic in an aging study designed to create a next-generation multi-omic aging clock.
May
2022
Seer VP of Proteomics, Daniel Hornburg, was interviewed by Authority Magazine to discuss how the study of multi-omics in space can improve our life on earth.
Apr
2022
Read more in Technology Networks about how profiling the plasma proteome could provide detailed insights into the health of individuals, as well as enabling earlier detection of a range of diseases.
Mar
2022
Read more in Clinical Lab Manager on how a plasma-based biomarker discovery platform for non-small cell lung cancer was developed using Seer’s unbiased proteogenomic approach to map protein variants arising from a single gene.
Mar
2022
Published results highlight simultaneous superior performance across depth, precision, and throughput versus conventional plasma proteomics workflows.
Mar
2022
Seer CEO Omid Farohkzad was profiled in the San Francisco Business Times. Read more on his unique career path, what inspires him to continue making an impact in life sciences, and his vision of proteomics for the future of healthcare.
Jan
2022
Seer, Discovery Life Sciences and SCIEX Announce First-Of-Its-Kind Proteogenomics Consortium for Large-Scale Studies.
Jan
2022
Seer Announces Broad Commercial Release of the Proteograph™ Product Suite and Launches Centers of Excellence Program.
Nov
2021
Researchers from the Oregon Health & Science University, the Broad Institute, Sanford Burnham Prebys Medical Discovery Institute, and proteomics software company Protein Metrics presented data and their experience using Seer’s Proteograph technology. (Premium content, sign in may be required.)
Nov
2021
Seer Welcomes Rachel Haurwitz, Ph.D. to Board of Directors
Oct
2021
Seer CEO Omid Farokhzad shares his perspective on how multidisciplinary approaches, including proteomics and genomics, will greatly expand our knowledge of biology and human health as part of Genetic Engineering & Biotechnology News’ 40th anniversary issue.
Oct
2021
This article in BioCentury explains how ‘omics technologies can improve the runway to drug approvals across diverse disease areas. For mass-spectrometry-based proteomic and metabolomic measurements the ability to capture a wider range of biological complexity is a more direct reflection of a patient’s state of health. (Subscription required)
Jul
2021
Dr. Omid Farokhzad, Chair, CEO and Founder of Seer, discusses how Seer’s cutting edge work with protein and proteomics is removing technological barriers and providing scientists with better tools to make breakthroughs than ever before. Watch the video here
Jul
2021
BioReport Podcast: CEO Omid Farokhzad explains why, although great progress has been made in understanding the human genome, the human proteome remains relatively unexplored.
Jun
2021
Motley Fool: interview with CEO Omid Farokhzad on the future of proteomics.
May
2021
Benzinga: interview with CEO Omid Farokhzad on the importance of proteomics
Mar
2021
Seer signs agreement with Sciex: Seer and SCIEX have signed a commercial agreement to provide end to end unbiased proteomics solutions.
Feb
2021
Seer adds board members: Seer appoints Deep Nishar and Mostafa Ronaghi, Ph.D. to its Board of Directors
Jan
2021
Seer and Bruker Sign Commercial Agreement to Expand Market for Unbiased, Deep Proteomics
Jan
2021
Seer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid and Large-Scale Proteomics
Dec
2020
Seer announced the pricing of its initial public offering of 9,210,527 shares of Class A common stock.
Sep
2020
Seer Appoints Catherine Friedman to its Board of Directors
Sep
2020
Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing
Jul
2020
Seers Announces Publication in Nature Communications Demonstrating Performance, Scalability and Utility of its Platform Technology for Deep, Unbiased Proteomics.
Jun
2021
Seer’s proprietary engineered nanoparticles. Each nanoparticle consists of a magnetic core and a surface with unique physicochemical properties.
Jun
2021
Proteins bind to Seer’s proprietary engineered nanoparticles first by concentration, and then by affinity displacement to form a protein corona.
Jun
2021
Seer’s Proteograph Product Suite is designed to enable unbiased, deep and rapid proteomics at scale.
May
2021
Reverse high resolution Seer logo in white for digital use.